Skip to main content
Back to Trials
NCT07594431PHASE2Recruiting

Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

Stanford University

Start Date

8/28/2026

Completion Date

8/1/2028

Summary

Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)

Eligibility Criteria

Age Range: 12 years to No maximum

80 patients with confirmed metastatic tumor (\>2.5 cm in short axis) will be enrolled, all ≥ 12 years of age with ECOG ≤ 2. All genders and races will be included. Inclusion Criteria: * Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer * One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: \>2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is \>2.5 cm in short axis * Age ≥12 * ECOG Performance Status 0-2 * For patients age 12-16, Lansky Play-Performance score 50-100 * Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential * All patients and/or their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent. Exclusion criteria: * Prior radiation therapy to the tumor to be treated * Active pregnancy * Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome * The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma

Interventions

RADIATION

LATTICE Radiotherapy

RADIATION

Standard radiotherapy

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

MetastasesMetastatic Cancer

Locations

Stanford University

Palo Alto, California 94304

United States